Diabetes, obesity & metabolism

Blood Sugar Changes After Stopping Semaglutide in Adults with Type 1 Diabetes Using Automated Insulin Delivery

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Changes in glycaemic control were evaluated after semaglutide discontinuation in adults with Type 1 diabetes and obesity.

  • Participants had previously completed the ADJUST-T1D randomized controlled trial.
  • The focus was on adults experiencing Type 1 diabetes alongside obesity.
  • Glycaemic control refers to the regulation of blood sugar levels.
  • Observations were made regarding the effects of stopping semaglutide treatment.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Oct '24
Glucose levels and low blood sugar episode length with once-weekly insulin icodec versus daily insulin glargine in people with type 2 diabetes starting insulin
top 1% journal
cited by 14 papers
randomized controlled trial
Dec '15
Liraglutide's effectiveness and safety for overweight adults with type 1 diabetes and poor blood sugar control
top 1% journal
cited by 155 papers
randomized controlled trial
Apr '22
Tirzepatide compared to placebo or semaglutide on insulin production and sensitivity in adults with type 2 diabetes
top 1% journal
cited by 219 papers
randomized controlled trial
Jun '26
GLP-1 receptor drug added to insulin helps control blood sugar during Ramadan fasting in diabetes
top 10% journal
journal article
Jun '19
Effectiveness and safety of oral semaglutide in type 2 diabetes patients with moderate kidney problems
top 1% journal
cited by 296 papers
randomized controlled trial
Jul '24
Effectiveness and safety of oral semaglutide alone compared to placebo in mostly Chinese adults with type 2 diabetes
top 2% journal
cited by 28 papers
randomized controlled trial
Jun '26
Adding Cagrilintide-semaglutide to basal insulin in adults with type 2 diabetes: a phase 3 trial
top 1% journal
cited by 7 papers
journal article
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 30 papers
systematic review
Jun '23
Effectiveness and safety of combining weekly doses of cagrilintide and semaglutide in type 2 diabetes
top 1% journal
cited by 258 papers
randomized controlled trial

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief